Christine Simmon

President & CEO Food and Drug Law Institute (FDLI) , Thought-leader, Innovator

[Christine Simmon @CSimmon_DC]

The 2021 U.S. Generic and Biosimilar Medicines Savings Report reveals that in 2020 alone, #biosimilars generated nearly $8 billion in savings, more than tripling 2019 savings. #GlobalBiosimilarsWeek

Read more in this blog post from the @BiosimsCouncil ⬇️https://t.co/Sz3UWStsSF

[Christine Simmon @CSimmon_DC]

The @BiosimsCouncil's comment to the @FTC today outlines harmful Pharmacy Benefit Manager practices: https://t.co/Qf1l6daZAe

#Biosimilars are lower cost options, but too often PBMs do not encourage their use.

[Christine Simmon @CSimmon_DC]

Today I will be joining @HCRoundtable for the webinar, "Biosimilars in the US: Benefits, Public Policies and Opportunities."

Register to hear perspectives from the @BiosimsCouncil and @Sandoz_Global on the evolving #biosimilar policy landscape: https://t.co/LDlKvHjBOq

[Christine Simmon @CSimmon_DC]

This is #MarkupMadness. Stop middlemen from adding to the cost of the generic prescription medicines millions of America’s patients rely on each day to manage their health! https://t.co/VRFCHLoEKo

[Christine Simmon @CSimmon_DC]

It was great to speak backstage with @LachmanConsult's Frances Zipp, @amcporg's Susan Cantrell (@amcpceo), and @Sandoz_Global's Keren Haruvi back stage at #Access2022! They shared great ideas about how to inspire the next generation of women in health care. #WiHP #Access2022

[Christine Simmon @CSimmon_DC]

Today at #Access2022, I will be joined by Martin Ares from @Sandoz_Global, Bret Jackson from @EAMOnline, Steven Allison from @AdventHealth and Steve Miller from @Cigna for "Leveraging Biosimilar Competition for Success."

You won't want to miss it!

[Christine Simmon @CSimmon_DC]

I said that I love you
But got back only crickets
Are you with the #biosimilars,
Stuck in the patent thickets?

#HealthPolicyValentines

[Christine Simmon @CSimmon_DC]

Valentine, I love you ❤️
And you say you love me
If Medicare Plans love #generics
Why are most now on brand tiers in Part D? 

Valentine, I need more of you
And I know our future is bright. 
Ditto for #biosimilars 💉
So let’s get the policies right.

#HealthPolicyValentines

[Christine Simmon @CSimmon_DC]

The @BiosimsCouncil looks forward to continuing our mission to increase patient access to #biosimilars this year.

Read our latest blog post to catch a glimpse into what's on our agenda in 2022: https://t.co/OqFdyDm1Oe

[Christine Simmon @CSimmon_DC]

Next week at #Access2022 I will be joined by Steven Allison (@stevenallisonrx), Martin Arès, Bret Jackson & Dr. Steve Miller to discuss the various stakeholders leveraging #biosimilar competition today.

Don't miss out! Register here: https://t.co/rimaPX6Oy8

@BiosimsCouncil

[Christine Simmon @CSimmon_DC]

At @AccessibleMeds & @BiosimsCouncil, we're looking forward to #Access2022, our preeminent conference taking place on Feb. 14-16.

I hope to see you all there in person in Orlando, FL to discuss what the future holds for the #biosimilars industry: https://t.co/zwNOsKokeS

[Christine Simmon @CSimmon_DC]

@gretchenrubin Piano

[Christine Simmon @CSimmon_DC]

Between participating in Global Biosimilars Week and hosting the GRx+Biosims 2021 conference, November was a busy month for the @BiosimsCouncil.

Read our November #Biosimilars Bulletin to learn more ➡️ https://t.co/4Ezf8v74e8

[Christine Simmon @CSimmon_DC]

The negotiation framework in #BuildBackBetter undermines tremendous savings generated by the #biosimilars industry and constrains patient access in the process.

The evidence is clear. Read our latest blog post from the @BiosimsCouncil to learn more: https://t.co/yMPPqANfr2

[Christine Simmon @CSimmon_DC]

#GRxBiosims 2021 is next week (Nov. 8-10), and I invite you to join @AccessibleMeds & the @BiosimsCouncil for three days packed with invaluable insights and information on #biosimilars & #generics from industry experts.

Register here ➡️ https://t.co/hhRk66Nf6O

[Christine Simmon @CSimmon_DC]

We are just one week away from #GRxBiosims 2021, and I invite you to join @AccessibleMeds & the @BiosimsCouncil virtually Nov. 8-10 to meet the leaders and decision-makers who are determining the future of generics and #biosimilars.

Register here ➡️ https://t.co/hhRk66Nf6O

[AAM @AccessibleMeds]

“The promise of #biosimilars is coming into view, but it won’t be fully realized until more policymakers & physicians understand the value proposition of these FDA-approved treatments.” — @CSimmon_DC @BiosimsCouncil

View report: https://t.co/M8XpB2qY8D #GRxBiosimsSavingsReport

[AAM @AccessibleMeds]

Congress is considering inflation-based rebate penalties in #Medicare to address high brand-name drug costs. AAM SVP @ErikCKomendant shares why this proposal could hurt competition & threaten #patientaccess to affordable #generic & #biosimilar medicines. https://t.co/KZuTXP85OO

[Christine Simmon @CSimmon_DC]

The #GRxBiosims 2021 virtual conference is November 8-10!

Join @AccessibleMeds & the @BiosimsCouncil for invaluable information & insights on generics and biosimilars from industry experts and government officials like @DrWoodcockFDA.

Register here ➡️ https://t.co/JBrxcZgnl6

[Christine Simmon @CSimmon_DC]

September was an exciting month for the @BiosimsCouncil as we announced the topline findings of our 2021 Generic Drug and Biosimilars Savings in the U.S. Report.

Read our September Biosimilars Bulletin here: https://t.co/10Gml7ClFW